Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences
TipRanks (Tue, 28-Apr 10:03 PM ET)
Globe Newswire (Wed, 22-Apr 7:00 AM ET)
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Tue, 7-Apr 4:50 PM ET)
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
Globe Newswire (Mon, 9-Mar 7:00 AM ET)
Globe Newswire (Tue, 3-Mar 9:05 AM ET)
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
Globe Newswire (Mon, 2-Mar 7:00 AM ET)
Globe Newswire (Thu, 19-Feb 7:00 AM ET)
Globe Newswire (Tue, 17-Feb 4:05 PM ET)
Market Chameleon (Tue, 6-Jan 4:55 AM ET)
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Novabridge Biosciences - American Depositary Shares trades on the NASDAQ stock market under the symbol NBP.
As of April 29, 2026, NBP stock price was flat at $2.39 with 1,189,636 million shares trading.
NBP has a beta of 0.93, meaning it tends to be less sensitive to market movements. NBP has a correlation of 0.03 to the broad based SPY ETF.
NBP has a market cap of $275.49 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that NBP belongs to (by Net Assets): IBB, SPEM, EWX, QQQS, GXC.
NBP support price is $2.27 and resistance is $2.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBP shares will trade within this expected range on the day.
